Apollomics, Inc., an innovative biopharmaceutical company dedicated to the discovery and development of new tumor-targeting and immune drugs and their combination therapies, announced that it has completed more than US$120 million in Series C financing. The financing was led by Ping An Capital, followed by several new and existing investors, and Huaxing Capital served as […]
Chinese Biopharma Firm Apollomics Completes $120M Financing comes from China Money Network: Primary Data for China’s Primary Markets! All Rights Reserved.